Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT-P38
- Development stage
- Preclinical
- Lead developer
- Teitur Trophics
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
TT-P38 is a novel SorCS2-derived peptide therapeutic being developed by Teitur Trophics for the treatment of sensorineural hearing loss. The drug targets the SorCS2 receptor pathway to selectively activate and enhance the endogenous production of Brain-Derived Neurotrophic Factor (BDNF) within the cochlea. By boosting BDNF levels, TT-P38 aims to promote neuroprotection and synaptic regeneration, specifically addressing cochlear synaptopathy. It is currently in preclinical development for indications including age-related hearing loss, noise-induced hearing loss, and hidden hearing loss, supported by the RE-HEAR project collaboration.
02
Targets
SORCS2 (Sortilin-related VPS10 domain-containing receptor 2)
Beyond the preview
Go deeper on TT-P38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT-P38.